Inquiry Basket
Synthetic oligonucleotides play pivotal roles in CRISPR-based genome editing. They are used to guide nucleases to the target site, as well as template repair of target sequences. Sequence, structure, and chemical modifications of guide RNAs and donor templates are all important considerations when designing CRISPR editing reagents. Guide RNAs should balance on-target activity with specificity. Donor templates should allow for enough homology to perform the desired genetic change. Consideration of these parameters is important for both research use and therapeutic application of CRISPR. As the technology moves forward, therapeutic use will require more extensive optimization of each element.
Chemically synthesized oligonucleotides are the programmable targeting vector and DNA repair template used in CRISPR nucleases. Targeting is achieved by Watson-Crick base pairing of the oligonucleotide with genomic DNA. In single guide RNAs, targeting is encoded by two components: a guide sequence of ~20 nucleotides that base pairs with the target and a scaffold sequence that binds to Cas nucleases. Assembled into a sgRNA, the oligonucleotide positions a molecular complex containing Cas nucleases to an arbitrary location defined by the ~20 nucleotide sequence within the genome. Synthetic single-stranded oligonucleotides may also be used as homology templates to induce a point mutation, addition of extra genetic material, or correction of a disease-causing mutation.
Fig. 1 Comparison of CRISPR–Cas9, base editor and prime editor.1,5
CRISPR-associated reagents include several classes of oligonucleotides. Guide RNAs are often twenty nucleotide-long sequences that target genomic regions near protospacer adjacent motif (PAM) sequences. The spacer sequence is placed on the 5' end of the guide RNA sequence and is used to direct Cas9-mediated cleavage. Single-stranded oligonucleotides used to introduce modifications via homology-directed repair often contain the desired mutation and include 30-90 nucleotide homology arms to facilitate strand invasion and template-dependent DNA synthesis. Homology arm length and symmetry can affect editing efficiency, with asymmetric homology arms being advantageous for certain targets. Modified-guide RNAs are used to direct deaminases to specific nucleotides for base editing, while prime editing utilizes a longer guide RNA fused to a reverse transcriptase template allowing for extensive edits without co-delivery of donor DNA.
| Component | Primary Function | Key Design Features |
| Guide RNA | Target recognition and nuclease recruitment | 20 nt spacer, PAM-adjacent positioning, GC content optimization |
| Single-stranded donor oligonucleotide | Template for homology-directed repair | Mutation-centered, homology arms 30-90 nt, strand selection |
| Repair oligonucleotide | Base editing or prime editing template | Modified guide structure, extended template sequence |
Table 1 Oligonucleotide Components in CRISPR Genome Editing
Guide RNAs must be optimized for target specificity. To design a guide RNA that will edit the genome at the desired location using CRISPR, scientists generally use algorithms and/or online tools which incorporate bioinformatic filters, thermodynamic properties, and secondary structure predictions. The necessary components to consider when designing a guide RNA include selection of a PAM sequence downstream of the target sequence, determination of the optimal nucleotide sequence for target site binding, and avoidance of DNA sequences which may cause the guide RNA to form secondary structures that would inhibit its function. Optimization parameters are distinct from typical oligonucleotide design by taking into account not just on-target efficiency, but potential off-target effects within the genome as a whole. Therefore, guide RNA design algorithms will often include a scoring system that analyzes the uniqueness of the guide RNA sequence within the context of the whole genome and predicts the thermodynamics of potential off-target sites. Guide RNA design becomes increasingly important as CRISPR gene editing enters into therapeutics.
Guide design begins with selecting a target site within the gene of interest. The main limitation for selection of this target site is the need for there to be a PAM sequence following it. For Cas9, the PAM sequence that is required is NGG (any base followed by two guanine bases). Variations of the PAM sequence, such as NAG, can sometimes work but will be less effective. This sequence is recognized by the Cas protein which then allows it to bind to the DNA and unwind the target strand. If this sequence is not present, then the DNA will not be cut. Once potential target sites have been identified within the coding region of a gene of interest, other factors to consider when selecting a target site are as follows: Make sure that the target site is not within a polymorphic region of the genome and does not target repetitive elements which could decrease the specificity of the-guide RNAs. Ideally, the cut made by the Cas9 should be as close to the middle of the gene as possible in order to affect protein function. Because the PAM sequence must be downstream of the target site DNA will be cut either upstream or downstream of the target site based on the orientation of the PAM sequence. This will affect whether the repair introduces a frameshift or precise edit.
The size of the guide RNA spacer sequence and the distribution of nucleotides along that sequence are also important factors for efficiency and specificity. Guide RNAs are traditionally composed of 20 nucleotides that are complementary to the target sequence. Using shorter spacer sequences can mitigate off-target effects, though at the cost of decreased affinity to the target site. Using lengths longer than 20 nucleotides has not been shown to greatly improve specificity and can lead to competing off-target cleavage sites. An optimal GC content for the spacer sequence is also important for efficient editing. A GC content between 40 and 60% is ideal because very low GC content will weaken binding affinity and editing efficiency. Alternatively, very high GC content can lead to the formation of secondary structures that sequester the guide sequence from its target or interact with other regions of the genome nonspecifically. Additionally, if the spacer sequence contains few to no repeats, high GC-content can lead to formation of intrastrand and interstrand structures. The specificity of editing can be affected by the position of certain nucleotides in the spacer sequence. Mismatches that occur closer to the PAM in the seed region (typically nucleotides 12-16) are less tolerated than those that occur further away.
Reducing off-target activity is a design goal for both research and clinical applications of CRISPR. Off-target activity can invalidate results of experiments and have adverse consequences in patients. When there are regions in the genome that are homologous to the sgRNA, CRISPR-Cas9 can cleave those sequences as well. There is more or less tolerance for mismatches between the sgRNA and the DNA target depending on their position in the sequence and which nucleotides are involved. Software tools can be used to predict off-target activity and design sgRNAs that will reduce it, and empirically testing sgRNA specificity is also possible. When selecting an sgRNA for a desired gene target, it is important to design one that will be specific to that target over thousands of potential off-target sites in the genome. Additionally, modifications to the guide RNA and use of high-fidelity Cas proteins can reduce off-target effects.
Mismatch tolerance between the CRISPR guide RNA and target DNA sequence varies along the 20 nt recognition sequence. Near the PAM, there is a region about 10–12 nucleotides in size known as the seed region that is particularly sensitive to mismatches; often a single base mismatch results in loss of cleavage efficiency. Tolerance increases further away from the PAM, allowing for up to one or three total mismatches in the guide/target complex before losing activity. Location and type of mismatch are key, with the least disruptive usually being either purine-purine mismatches or pyrimidine-pyrimidine mismatches. Bioinformatic programs use position-dependent cutoffs to score potential off-target sites throughout the genome based on location and type of mismatches as well as overall "energy" of the mismatched duplex. Several high-fidelity Cas variants have been engineered with mutations in the REC3 domain that raises the energetic barrier of mismatched duplexes. These mutations have been shown to extend the seed region's specificity throughout the entire guide sequence, although some GUIDEsequences may lose activity on their target site.
Computational prediction represents one strategy to limit off-target effects. Algorithms allow for in silico screening of entire genomes for guide RNAs that have limited homology to other sites within the genome. Programs like Cas-OFFinder, CRISPOR, and CHOPCHOP use sequence alignment methods to identify potential off-target sites that have up to a specified number of mismatches. More sophisticated versions of these algorithms integrate machine learning methods to predict cleavage likelihood based on training datasets. These machine learning methods take into account various features that affect target binding including chromatin state, sequence complementarity, and DNA/RNA thermodynamics. GUIDE-seq, CIRCLE-seq or site-specific amplification and sequencing can subsequently be used to validate computationally predicted guide RNAs for lack of off-target cleavage. Computational design iterated with experimental validation can be used to identify guide RNAs with high specificity for sensitive applications like gene therapy.
Activity of CRISPR guides is determined in part by their folding potential and chemical stability. These properties determine target accessibility, protein interaction, and susceptibility to degradation in biological systems. Guide RNAs require secondary structures that allow them to bind both their target and protein partners (such as Cas nucleases) simultaneously. Secondary structure within the guide itself can cause sequestering of the target sequence, reducing activity. Guides are also susceptible to degradation by nucleases, reactive oxygen species, and denaturation due to chemical instability when inside cells and organisms. Improving folding specificity and chemical stability through guide design and modification is therefore necessary to create useful guides.
Guide RNAs can form intrastrand secondary structures. Guide RNAs that form stable hairpins greatly reduce the efficacy of gene targeting as the targeting sequence becomes trapped within the hairpin and cannot hybridize with genomic DNA. The minimum free energy folding of guide RNAs can predict structured RNAs that would form stable hairpins. Folding values that are less than 0 indicate stable stem-loops will form. Folding values that are greater than 0 indicate that the RNA will not form a stable structure and the unfolded state is favored allowing for interaction with the target. As sgRNAs contain a constant scaffold sequence that forms a specific stem-loop structure necessary for Cas protein binding, over folding or alternative folding of the variable targeting sequence will greatly reduce its activity. During sgRNA design software will score sequences based on thermodynamic stability of their target as well as their ability to avoid creating structures. As mentioned above if the guideRNA folds onto itself it will not be able to interact with its target. Special emphasis is placed on the formation of structures at the 5'-end of the guideRNA as these will sterically hinder target interaction as well as prevent R-loop formation.
Chemically modifying the guide RNA also improves stability in vivo. These modifications prevent degradation by nucleases and tune binding strength without interfering with protein binding. The most common chemical modification is adding two-prime (2') methoxy or fluoro groups. This modification prevents degradation by exonucleases and strengthens binding to target DNA. However, these modifications cannot occur on the scaffold sequence necessary for binding to Cas as they need to occur on the targeting sequence of the guide. Guide RNAs with greater stability will have longer half lives in vivo. Modifying the phosphates to phosphorothioates on the 5' and 3' ends of guide RNAs can also prevent degradation by endonucleases. Phosphorothioate modifications can also increase cellular uptake in conjunction with delivery agents. The addition of these modifications needs to be optimized since over modification can hinder functionality.
Site-directed mutagenesis can be accomplished by homology-directed repair with synthetic donor oligonucleotides. This approach leverages endogenous DNA repair pathways to introduce specified sequence alterations. Instead of a templated insertion/deletion as seen with non-homologous end joining, homology directed repair introduces site-specific DNA alterations through exogenously supplied donor templates. This donor DNA then undergoes repair following Cas nuclease cleavage to effect genetic changes at the site of the cut. Key elements of the donor DNA template such as overall structure, length of homology arms, and strand polarity all affect repair efficiency and fidelity. Single-stranded versus double-stranded donors impact efficiency, size of insertions, and delivery methods. Length and balance of homology arms are also important and can affect the kinetics of strand invasion and repair. Ultimately, the strategy used for donor template design can vary depending on the end goal, whether that be point mutations, integration of a reporter gene, or correction of a disease mutation.
Oligonucleotides used as donors can be either single-stranded DNA or double-stranded DNA. Editing efficiencies are often higher with ssDNA donors in a variety of cell types. These ssDNA donors are typically between 90 and 200 nucleotides in length and can be targeted with less immune stimulation than dsDNA donors. The orientation of the donor oligo matters as well; DNA polymerase displaces one strand of DNA upon repair. The strand complementary to this non-target strand, called the anti-sense strand, often has higher efficiency based on binding of replication protein A and strand invasion by Rad51. Longer donors or donors containing larger inserts can be made using double-stranded DNA templates. These inserts can range from several kilobases in length. Double-stranded DNA donors can be plasmids or amplified using PCR. Double-stranded DNA can activate the DNA damage response pathway, potentially interfering with desired genomic modifications. Double-stranded DNA can also be recognized by cytosolic DNA sensors which initiate innate immune signaling pathways.
The size and orientation of homology arms relative to your intended modification impacts HDR efficacy. Homology arms are typically between 30 and 90 nt homologous sequences that flank your modification of interest. Increasing homology arm length tends to increase repair efficiency as it stabilizes strand invasion intermediates and increases the amount of template available for DNA synthesis. However, longer homology arms make DNA synthesis more difficult and may increase off-target integration or recombination events. Taller arms on one side of the modification have been shown to increase efficiency in some contexts. This may be due to asymmetric strand invasion and displacement during repair. It has also been suggested that optimal repair occurs when your modification lies 10-20nt away from your double strand break. This keeps your modification close enough to the cleavage site that incorporation is likely while decreasing likelihood of indels forming where the donor sequence joins genomic DNA.
Synthetic oligonucleotide quality is therefore one of the major factors affecting CRISPR success rates, with key consequences for targeting specificity, cleavage activity, and homology-directed repair accuracy. Even though some applications can tolerate relatively high levels of impurities, CRISPR approaches can be sensitive to sequence and chemical purity because targeting is dictated by the specific molecular interactions between the guide RNA and the Cas nuclease. Degraded guide RNAs, chemically altered guides, or impurities that vary from synthesis batch to batch can lead to unexpected genome editing activities, such as lower efficiency, increased off-target effects, or inhibition of HDR. High-quality controls are especially important for therapeutic CRISPR applications.
Fig. 2 The molecular mechanism of the CRISPR-Cas9 system is depicted in a schematic picture.2,5
Synthetic sgRNAs and DNAs will have associated impurities that affect CRISPR efficiency and reproducibility. Truncated non-functional sgRNAs (failures), especially those missing the last nucleotide (n-minus-ones), can bind Cas but not efficiently cleave target DNA. In the case of purified RNAs for RNP transfection, they compete with functional sgRNAs for Cas binding. The higher their relative concentration, the lower the concentration of active editing molecules (be they RNPs or editing templates), and therefore the editing efficiency. Presence of failures can cause variability in editing efficiency between preparations. Overall guide length also affects specificity. Guide RNAs of incorrect length (including sgRNAs that are one nt shorter or longer than the desired 20 nt length) can cause off-target cleavage. Variability in sgRNA purity between different synthesis preparations can also cause variability between experiments run at different times.
The most critical applications for CRISPR products are therapeutic uses where product quality requirements are very high. A number of analytical tests and manufacturing controls are required that go beyond research-quality molecules. Mass spectrometry provides identity confirmation based on matching molecular weight with the intended sequence. High-resolution chromatography provides purity specifications and typically can separate closely related impurities such as stereoisomers or modified forms. Editing activity is validated in an appropriate cellular model, which sets a specification for biological activity in addition to chemical quality. Storage and stress stability ensures the oligonucleotide quality remains stable over time and use so that degradation does not negatively impact performance of the therapeutic product. Regulatory manufacturing of CRISPR therapies is carried out with good manufacturing practice (GMP) compliance.
| Quality Attribute | Analytical Method | Impact on CRISPR Performance |
| Full-length purity | HPLC, capillary electrophoresis | Determines effective concentration of functional guides |
| Length accuracy | Mass spectrometry | Influences binding affinity and specificity |
| Modification integrity | Mass spectrometry, HPLC | Affects stability and activity |
| Batch consistency | In-process testing, release assays | Ensures reproducible editing outcomes |
Table 2 Quality Parameters for CRISPR Oligonucleotides and Their Impact
Custom CRISPR oligos are typically required when desired specifications are not met by available, off-the-shelf reagents. Off-the-shelf CRISPR guides are typically adequate for basic gene knockouts in standard cellular assays. More complex experiments or therapeutic applications require custom designed guides. This can include precise base pair editing, insertions, or drug development. These applications often require custom chemical modifications and stringent quality controls. Additionally, clinical development of CRISPR reagents requires custom made oligos with Quality Management Documentation including batch to batch testing and validated test methods. Custom oligo design allows for the optimization of nucleotide sequence, modifications, and secondary structure for desired target, cell type, and application.
Another reason therapeutic applications of gene editing typically utilize custom oligos is due to regulatory requirements. Gene editing for use in humans requires extensive safety testing, meaning that researchers looking to develop a therapeutic will have to identify the optimal targeting sequences (those with highest editing efficiency while lacking off-target effects) well in advance of in vivo testing. Once these sequences are identified, they need to be purchased/built in bulk with guaranteed batch consistency (P2P products cannot provide this). This manufacturing process needs to be carried out under good manufacturing practice (GMP) conditions. Furthermore, many chemical modifications that improve stability, minimize immune reactions, and increase specificity (see Chemistry considerations section) require custom design. Finally, gene editing therapeutics generally do not simply introduce a double stranded break at a locus. Whether performing precise correction of a point mutation or insertion of a therapeutic cassette, designer donor oligos with precise placement of modifications and homology arm lengths are needed.
Many complex CRISPR applications necessitate custom oligos. High-throughput screening libraries, multiplexed editing pools, and cutting-edge CRISPR technologies like base editing or prime editing often require guide RNAs with specialized formats. GUIDE-ITS enables you to order constructs with non-standard lengths—like long sequences needed for pegRNAs or unique spacer lengths needed for certain base editors—and modifications that enable affinity purification, fluorescent labeling, or optimized chemical properties for delivery or stability. If you're targeting a difficult-to-reach locus or need ultra-high specificity, you may need to test multiple guide RNA sequences and modifications to dial in the performance you need. Custom synthesis allows you to rapidly prototype these designs.
| Application Context | Standard Reagent Limitation | Custom Solution | Key Benefit |
| Therapeutic development | Inadequate purity, lack of GMP documentation | GMP manufacturing with full characterization | Regulatory compliance, patient safety |
| Precise genome editing | Limited availability of donor templates | Custom-designed HDR templates with exact homology arms | Accurate modification placement |
| Novel CRISPR modalities | Absence of specialized guide architectures | Extended or modified guide RNA designs | Support for base editing, prime editing |
| Hard-to-target loci | Suboptimal performance of catalog guides | Iterative sequence optimization | Enhanced editing efficiency and specificity |
| In vivo applications | Insufficient stability or immunogenicity | Chemically modified, nuclease-resistant sequences | Extended activity, reduced |
Table 3 Indicators for Custom CRISPR Oligonucleotide Design
Effective CRISPR genome editing depends not only on target selection but also on the structural integrity and chemical quality of guide RNAs and donor oligonucleotides. Design decisions directly influence editing efficiency, specificity, and experimental reproducibility. Our expertise in CRISPR-related oligonucleotides includes:
By integrating rational design principles with controlled synthesis and purification processes, CRISPR oligonucleotides can be optimized to support reliable genome editing performance.
Low editing efficiency, unexpected off-target effects, or inconsistent experimental results may stem from guide RNA design limitations or oligonucleotide quality constraints. A technical evaluation may be beneficial if your CRISPR program involves:
Aligning sequence design with synthesis feasibility and purification requirements early in the workflow can reduce troubleshooting cycles and improve overall editing success. Contact our team to discuss your CRISPR oligonucleotide design and synthesis requirements and determine the most appropriate strategy for your application.
References
